A5048875338- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Systemic Lupus Erythematosus Research
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Treatment and Pharmacology
- Medical Imaging Techniques and Applications
- Platelet Disorders and Treatments
- Sulfur Compounds in Biology
- Esophageal Cancer Research and Treatment
- Renal Diseases and Glomerulopathies
- Radiomics and Machine Learning in Medical Imaging
- RNA Research and Splicing
- Epigenetics and DNA Methylation
- Ferroptosis and cancer prognosis
- Complement system in diseases
- Fibroblast Growth Factor Research
- Cancer Cells and Metastasis
- Acute Kidney Injury Research
- Redox biology and oxidative stress
- Single-cell and spatial transcriptomics
- Liver Disease Diagnosis and Treatment
- Electron Spin Resonance Studies
- Breast Cancer Treatment Studies
The First Affiliated Hospital, Sun Yat-sen University
2017-2023
Zhongshan Hospital
2017-2023
Fudan University
2017-2023
Sun Yat-sen University
2017-2023
State Key Laboratory of Genetic Engineering
2022
Xiangyang Central Hospital
2021
First Affiliated Hospital of Chengdu Medical College
2021
Peking University First Hospital
2016-2018
Peking University
2016-2018
Ministry of Education of the People's Republic of China
2016-2018
BackgroundEsophageal squamous cell carcinoma (ESCC) is among the most prevalent causes of cancer-related death in adults. Tumor microenvironment (TME) has been associated with therapeutic failure and lethal outcomes for patients. However, published reports on heterogeneity TME ESCC are scanty.MethodsFive tumor samples five corresponding non-malignant were subjected to scRNA-seq analysis. Bulk RNA sequencing data retrieved publicly available databases.FindingsFrom data, a total 128,688 cells...
Esophageal squamous cell carcinoma (ESCC) accounts for 90% of all cases esophageal cancers worldwide. Although neoadjuvant chemotherapy (NACT-ESCC) improves the survival ESCC patients, five-year rate these patients is dismal. The tumor microenvironment (TME) and heterogeneity decrease efficacy therapy. In our study, 113,581 cells obtained from five who underwent surgery alone (SA-ESCC) preoperative paclitaxel plus platinum (NACT-ESCC), were used scRNA-seq analysis to explore molecular...
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with poor prognosis. Proteogenomic characterization and integrative proteomic analysis provide functional context to annotate genomic abnormalities prognostic value. Methods We performed an integrated multi-omics analysis, including whole-exome sequencing, RNA-seq, proteomic, phosphoproteomic of 217 PDAC tumors paired non-tumor adjacent tissues. In vivo experiments were further illustrate the biological...
Objective This study aimed to evaluate the clinical value of urinary biomarkers including kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and monocyte chemoattractant protein-1 (MCP-1) in lupus nephritis. Methods A total 109 biopsy-proven nephritis patients were included 50 healthy individuals used as normal controls. Urinary KIM-1, NGAL, MCP-1 levels measured by ELISA their correlations with histological features assessed. Receiver operating...
Objective Our previous study showed that plasma levels of factor H (FH) were significantly decreased in patients with lupus nephritis and reflected activity. The aim this was to further investigate vitro biofunctions FH nephritis. Methods purified from the first run exchange four active two non-renal involvement systemic erythematosus (SLE) patients, healthy controls. Then, analyzed. In addition, exons sequencing analysis performed. Results Homogeneous fractions purity comparable commercial...
Abstract Background: There is no standard of care for neoadjuvant or adjuvant therapy resectable hepatocellular carcinoma (HCC) yet. This trial designed to explore the safety and efficacy toripalimab in combination lenvatinib as peri-operative treatment HCC. (NCT03867370) Methods: In this ongoing phase Ib/II trial, patients (pts) with HCC who are eligible surgical resection enrolled. part study, pts Arm A given 480 mg iv single dose B treated 480mg plus concurrent 12 8 daily orally (based on...
e16220 Background: The combination of Sintilimab (a PD-1 antibody) and bevacizumab (bev) biosimilar improved progression-free survival overall in unresectable or advanced HCC as compared with sorafenib ORIENT-32 study was approved first-line treatment for China. We assessed the efficacy safety therapy conversion potentially resectable intermediate-stage HCC. Methods: Treatment-naïve patients (pts) intermediate stage (BCLC B) were enrolled this phase II trial (NCT04843943). Eligible pts...
Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer for which effective therapeutic agents are lacking. Fibroblast growth factor receptor 2 (
Programmed cell death ligand 1 (PD-L1) expression plays an important role in selecting patients with hepatocellular carcinoma who will benefit from anti-programmed (PD-1)/PD-L1 monotherapy and directing those lower levels to alternative treatments. In total, 156 tumors were stained three PD-L1 immunohistochemistry assays (SP142, 28-8, E1L3N). Two junior pathologists one senior pathologist evaluated the pathological slides recorded percentages of tumor immune cells at any intensity....
Abstract In this study, 422 female patients who presented with clinical indications and underwent ultrasound (US), mammography (MMG), breast specific gamma imaging (BSGI) before surgery during the period from July 2013 to June 2015 were retrospectively reviewed. Twenty-two of had no pathological report available excluded. These both mammographic examinations initially. If US MMG positive, patient was recommended for a BSGI examination pre-surgical planning. A also negative or indeterminate...
Abstract Background Clear cell renal carcinoma (ccRCC) accounts for almost 75% of all cancers, with high heterogeneity and poor prognosis. There is increasing evidence that alternative splicing (AS) associated tumorigenesis immune microenvironment. However, studies on the relationship between AS events immunity in ccRCC are still few but needed. Methods The transcriptional data clinicopathological information patients were downloaded from Cancer Genome Atlas (TCGA) database. We grouped...